A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

← catalyst calendar

NCT05536804 · readout ≤ 42 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

140estimated

Sites

Countries

Austria, Canada, Denmark +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-02-08

actual

When the study began enrolling

Primary completion

Sep 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Oct 2026

estimated

The whole study's end, after follow-up

First posted

2022-09-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-08

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Overweight
Obesity
Chronic Kidney Disease
Type 2 Diabetes
T2D

Interventions

Drug: Tirzepatide
Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF

Percent Change from Baseline in Renal Sinus Fat Content (MRI)

measured Baseline, Week 52

Publications

PMID 40512543 — linked by the registry
PMID 39963952 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed